Dijagnostička i terapijska efikasnost hidrodistenzije mokraćne bešike kod bolesnika sa sindromom bolne bešike
Sažetak
Uvod/Cilj. Intersticijski cistitis (IC)/sindrom bolne bešike (SBB) je stanje ponavljajuće nelagodnosti ili bola u mokraćnoj bešici i okolnom karličnom regionu bez prepoznatljive bolesti. Cilj rada bio je da se kod bolesnika sa SBB proceni značaj hidrodistenzije kao dijagnostičke i terapijske procedure. Metode. Prospektivnom studijom obuhvaćeno je ukupno 45 bolesnika podvrgnutih cistoskopiji sa hidrodistenzijom. Srednje vrednosti za parametre učestalost 24-časovnog mokrenja, zapremina maksimalno izmokrenog urina, zapremina prosečno izmokrenog urina i zapremina minimalno izmokrenog urina dobijene su iz „dnevnika mokrenja“. Ove vrednosti su upoređivane između vremena pre hidrodistenzije i jedan, tri i šest meseci posle toga. Rezultati. Poređenjem početnih podataka i podataka iz sva tri perioda praćenja (posle 1, 3 i 6 meseci) utvrđena je statistički značajna razlika (p < 0,046), i to: za 24-časovnu učestalost mokrenja, bila je 19,64 ± 3,56, 9,42 ± 1,71, 9,58 ± 1,45 i 12,2 ± 2,79, redom; zatim, za minimalnu zapreminu urina (p < 0,03), bila je 59,11 ± 23,72 mL, 114,89 ± 4,09 mL, 112,44 ± 100,86 mL i 89,00 ± 29,45 mL, redom; za prosečnu zapreminu mokrenja (p < 0,04), bila je 105,33 ± 18,29 mL, 186,89 ± 23,14 mL, 186,44 ± 21,44 mL i 155,78 ± 30,78 mL, redom. Nije bilo statistički značajne razlike (p < 0,1) za vrednosti maksimalne zapremine izmokrenog urina između početnih i kontrolnih intervala: 196,89 ± 43,68 mL, 312,89 ± 54,59 mL, 316,00 ± 49,47 mL, 266,67 ± 53,17 mL, redom. Zaključak. Rezultati našeg istraživanja ukazuju na to da je hidrodistenzija pouzdana dijagnostička i terapijska procedura.
Reference
Parsons JK, Parsons CL. The historical origins of interstitial cys-titis. J Urol 2004; 171(1): 20–2.
Gillenwater JY, Wein AJ. Summary of the national institute of arthritis, diabetes, digestive and kidney diseases workshop on interstitial cystitis, national institutes of health, Bethesda, Maryland, August 28−29, 1987. J Urol 1988; 140(1): 203–6.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21(2): 167–78.
Van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cer-vigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cysti-tis: an ESSIC proposal. Eur Urol 2008; 53(1): 60–7.
Abrams P, Andersson KE, Apostolidis A, Birder L, Bliss D, Bru-baker L, et al. Sixth International Consultation on Inconti-nence Recommendations of the International Scientific Committee: Evaluation and treatment of uri-nary incontinence, pelvic organ prolapse, and faecal inconti-nence. Neurourol Urodyn 2018; 37(7): 2271−2.
European Association of Urology. Chronic pelvic pain [Internet]. The Netherlands: EAU. 2016 [cited 2024 July 2]. Available from: https://uroweb. org/guideline/chronic-pelvic-pain/#1
Bumpus HJ. Interstitial cystitis: its treatment by over-distention of the bladder. Med Clin North Am 1930; 13: 1495–8.
Hand JR. Interstitial cystitis; report of 223 cases (204 women and 19 men). J Urol 1949; 61(2): 291–310.
American Urology Association. Diagnosis and treatment of inter-stitial cystitis/bladder pain syndrome [Internet]. Linthcum: AUA; 2016 [cited 2024 July 2]. Available from: https://www.auanet.org/common/pdf/education/clinical-guidance/IC-Bladder-Pain-Syndrome-Revised.pdf
Homma Y, Akiyama Y, Tomoe H, Furuta A, Ueda T, Maeda D, et al. Clinical guidelines for interstitial cystitis/bladder pain syndrome. Int J Urol 2020; 27(7): 578–89.
Tirlapur SA, Birch JV, Carberry CL, Khan KS, Latthe PM, Jha S, et al. Management of bladder pain syndrome. BJOG 2016; 124(2): e46–72.
D’Ancona C, Haylen B, Oelke M, Abranches-Monteiro L, Arnold E, Goldman H, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn 2019; 38(2): 433−77.
Homma Y, Ueda T, Tomoe H, Lin AT, Kuo HC, Lee MH, et al. Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015. Int J Urol 2016; 23(7): 542−9.
Hunner GL. A rare type of bladder ulcer in women; report of cases. Boston Med Surg J 1915; 172: 660–4.
Clemens JQ, Erickson DR, Varela NP, Lai HH. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol 2022; 208(1): 34−42.
Hanno P, Cervigni M, Choo MS, Clemens JQ, Lee MH, Malde S, et al. Summary of the 2023 report of the international consul-tation on incontinence interstitial cystitis/bladder pain syn-drome (IC/BPS) committee. Continence 2023; 101056.
Yoshimura N, Uno T, Sasaki M, Ohinata A, Nawata S, Ueda T. The O'Leary-Sant Interstitial Cystitis Symptom Index is a clin-ically useful indicator of treatment outcome in patients with interstitial cystitis/bladder pain syndrome with Hunner le-sions: A post hoc analysis of the Japanese phase III trial of KRP-116D, 50% dimethyl sulfoxide solution. Int J Urol 2022; 29(4): 289−96.
Malde S, Palmisani S, Al-Kaisy A, Sahai A. Guideline of guide-lines: bladder pain syndrome BJU Int 2018; 122(5): 729−43.
Kirk PS, Santiago-Lastra Y, Qin Y, Stoffel JT, Clemens JQ, Cam-eron AP. The effects of cystoscopy and hydrodistention on symptoms and bladder capacity in interstitial cystitis/bladder pain syndrome. Neurourol Urodyn 2018; 37(6): 2002–7.